{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:47:33Z","timestamp":1791827253556,"version":"4.3.4"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/cad.0000000000000040","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T05:07:25Z","timestamp":1383282445000},"page":"140-149","source":"Crossref","is-referenced-by-count":140,"title":["Histone deacetylase inhibitors"],"prefix":"10.1097","volume":"25","author":[{"given":"Marije","family":"Slingerland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210227","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer.","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"R2-2-20210227","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","article-title":"The epigenetic progenitor origin of human cancer.","volume":"7","author":"Feinberg","year":"2006","journal-title":"Nat Rev Genet"},{"key":"R3-2-20210227","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg2005","article-title":"Cancer epigenomics: DNA methylomes and histone-modification maps.","volume":"8","author":"Esteller","year":"2007","journal-title":"Nat Rev Genet"},{"key":"R4-2-20210227","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function.","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"R5-2-20210227","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors.","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R6-2-20210227","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","article-title":"Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation.","volume":"68","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Cancer Res"},{"key":"R7-2-20210227","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1038\/sj.onc.1204853","article-title":"Transcriptional regulation in acute promyelocytic leukemia.","volume":"20","author":"Lin","year":"2001","journal-title":"Oncogene"},{"key":"R9-2-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"key":"R10-2-20210227","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past, present and future.","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R11-2-20210227","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent.","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"R12-2-20210227","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"R22-2-20210227","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R25-2-20210227","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-011-1762-1","article-title":"A randomized phase II study of two doses of vorinostat in combination with 5-FULV in patients with refractory colorectal cancer.","volume":"69","author":"Fakih","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R30-2-20210227","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7164\/antibiotics.47.311","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination.","volume":"47","author":"Shigematsu","year":"1994","journal-title":"J Antibiot"},{"key":"R37-2-20210227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A phase II study of depsipeptide in refractory metastatic renal cell cancer.","volume":"5","author":"Stadler","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"R41-2-20210227","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/JTO.0b013e3181ec1713","article-title":"Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).","volume":"5","author":"Otterson","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R61-2-20210227","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2011.590568","article-title":"A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.","volume":"29","author":"Hainsworth","year":"2011","journal-title":"Cancer Invest"},{"key":"R62-2-20210227","first-page":"1027","article-title":"Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.","volume":"32","author":"Wang","year":"2012","journal-title":"Anticancer Res"},{"key":"R70-2-20210227","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"R77-2-20210227","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.9.9.11436","article-title":"Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.","volume":"9","author":"David","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R90-2-20210227","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1158\/1078-0432.CCR-06-1017","article-title":"Challenges of evaluating the cardiac effects of anticancer agents.","volume":"12","author":"Bates","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R92-2-20210227","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0000000000000040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:32Z","timestamp":1786039412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201402000-00002"}},"subtitle":["an overview of the clinical studies in solid tumors"],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000040","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}